Leishmaniasis ALGERIA 2014
Total Page:16
File Type:pdf, Size:1020Kb
Leishmaniasis ALGERIA 2014 Published in July 2016 Country General Information (WHO, 2013) Total population: 39,208,000 Age group <15/>14 years, %: 28% / 72% Gender (%, F/M): 49.4% / 50.6% Life expectancy at birth in years (F/M): 73 / 69 GDP (PPP int $): 12 990 Number of 3rd sub-national administrative level 1541, Baladiyah Income status: Upper middle divisions, name: Epidemiology VL CL PKDL MCL Endemicity status: Endemic Endemic Non endemic Non endemic Number of new cases (incidence): 30 5423 N/A N/A Number of relapse cases: No data No data N/A N/A Total number of cases: 30 5423 N/A N/A Imported cases (#, %): No data No data No data No data Gender distribution (% F): No data No data N/A N/A Age group distribution (%, <5/5-14/>14): No data No data No data N/A Incidence rate (cases/10 000 population in endemic 0.01a 5.42 N/A N/A areas): Number of endemic 3rd sub-national administrative level No data 328 N/A N/A divisions (n): (10005224/ Population at risk1 (%, n/total): No data 26% N/A N/A 39208000) Was there any outbreak? No No N/A N/A Number of new2 foci: 0 0 N/A N/A N/A = not applicable VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis MCL = mucocutaneous leishmaniasis Monthly distribution of new cases January-December 2014 JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC VL No data No data No data No data No data No data No data No data No data No data No data No data CL No data No data No data No data No data No data No data No data No data No data No data No data Number of new CL cases reported by month in Number of new (primary) VL cases reported by 2013 and 2014* month in 2013 and 2014* CL 2014 5 5 CL 2013 VL 2014 VL 2013 4 4 3 3 2 2 Numberof new CL cases 1 1 0 0 Number of new (primary) VL cases JUL SEP FEB JUL JAN SEP JUN FEB APR DEC JAN OCT JUN DEC APR OCT AUG NOV MAY MAR AUG NOV MAY MAR Indicence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014 Number of cases and incidence rate3 of CL CL cases Number of cases and incidence rate3 of VL CL incidence rate VL cases 35000 10.0 250 0.08 VL incidence rate 9.0 0.07 30000 8.0 200 0.06 25000 7.0 0.05 20000 6.0 150 5.0 0.04 15000 4.0 100 0.03 10000 3.0 0.02 Incidence rate (/10 000) (/10 rateIncidence 2.0 Incidence000)rate(/10 Number of CL of Number cases 50 5000 cases VL of Number 1.0 0.01 0 0.0 0 0 19… 19… 20… 20… 20… 20… 20… 20… 20… 20… 20… 20… 20… 20… 20… 20… 20… 1998 2000 2002 2003 2004 2005 2006 2007 2009 2011 2012 2013 2014 1999 2001 2008 2010 a For VL, the incidence rate was calculated for the total population * No data available 1 Defined as “Number of people living in 3rd sub-national administrative level endemic areas” 2 For this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever 3 Incidence rate at the national level Distribution of new CL (left) and new (primary) VL (right) cases Incidence of CL in Algeria in 2014 at baladiyah level per 10 000 population Incidence of VL in Algeria in 2014 at wilaya level per 10 000 population The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map production: WHO/HTM/NTD/IDM Control and surveillance Year Leishmaniasis National Control 2006 Year latest national guidelines were published: 2010 Programme (LNCP) was established: Type of surveillance: Integrated Is leishmaniasis a notifiable disease (mandatory reporting)? Yes Is there a vector control programme? Yes Is there a reservoir host control programme? No Type of insecticide used for IRS: Pyrethroids Number of leishmaniasis health facilities: 488 Diagnosis VL CL PKDL MCL Number of people screened actively for: No data No data N/A N/A Number of people screened passively for: No data No data N/A N/A VL cases diagnosed by RDT* No data N/A N/A N/A (%, # RDT+/total VL cases): Proportion of positive RDT* No data N/A N/A N/A (%, # RDT+/total RDT): Cases diagnosed by direct exam No data 100% (5423/ 5423) N/A N/A (parasitology) (%, # slides +/total cases): Proportion of positive slides No data 100% (5423/ 5423) N/A N/A (%, # slides +/total slides): Cases diagnosed clinically No data 0 N/A N/A (%, # clinical cases/total cases): Percentage of cases with HIV-VL coinfection: No data N/A No data N/A * These indicators apply only for new (primary) VL cases VL = visceral leishmaniasis CL = cutaneous leishmaniasis PKDL = post-kala-azar dermal leishmaniasis N/A = not applicable RDT = rapid diagnostic test HIV = human immunodeficiency virus MCL = mucocutaneous leishmaniasis Treatment and medicines Is treatment provided free of charge in the public sector? Yes Antileishmanial medicines included in the national List of Essential Medicines: Amphotericin B deoxycholate, liposomal amphotericin B, meglumine antimoniate TREATMENT OUTCOME VL Proportion of relapse cases:4 No data Initial cure rate: No data Failure5 rate: No data Case-fatality rate: No data 4 A relapse case in this country is defined as: No definition available Data source: National reference laboratory for leishmaniasis, Pasteur Institute, Algeria WHO 2014. All rights reserved. 5 A failure case in this country is defined as: No definition available.